ABSTRACT

Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor in development for treating gout and asymptomatic hyperuricaemia. This phase IIa study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad combined with allopurinol versus allopurinol alone in adults with gout.

Methods Forty-one subjects were randomised into two cohorts of verinurad (2.5–20 mg plus allopurinol 300 mg once daily) versus allopurinol 300 mg once daily, 600 mg once daily or 300 mg twice daily alone. Each treatment period was 7 days. Serial plasma/serum and urine samples were assayed for verinurad, allopurinol, oxypurinol and uric acid.

Results Serum pharmacodynamic data pooled across cohorts demonstrated maximum per cent decreases in serum urate (sUA) from baseline (E\text{max}) at 7–12 hours after verinurad plus allopurinol treatment. Combination treatment decreased sUA in dose-dependent manner: least-squares means E\text{max} was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily, respectively. Verinurad had no effect on allopurinol plasma pharmacokinetics, but decreased oxypurinol C\text{max} by 19.0%–32.4% and area under the plasma concentration–time curve from time zero to the last measurable time point by 20.8%–39.2%. Verinurad plus allopurinol was well tolerated with no serious adverse events (AEs), AE-related withdrawals or renal-related events. Laboratory values showed no clinically meaningful changes.

Conclusion Verinurad coadministered with allopurinol produced dose-dependent decreases in sUA. All dose combinations of verinurad and allopurinol were generally well tolerated. These data support continued investigation of oral verinurad in patients with gout.

Trial registration number NCT02498652.

INTRODUCTION

Gout is characterised by the deposition of monosodium urate crystals in the joints, tendons and other connective tissues, secondary to long-standing hyperuricaemia.\(^1\)–\(^3\) Reducing the concentration of serum urate (sUA) below its saturation point leads, over time, to the dissolution of crystals and the alleviation of gout symptoms.\(^1\)\(^5\) To achieve this goal, patients typically require long-term urate-lowering therapy (ULT) in addition to lifestyle and dietary changes.

What is already known about this subject?

- Many patients with gout do not achieve their serum urate (sUA)-lowering targets during treatment with a xanthine oxidase inhibitor (XOI), for example, allopurinol or febuxostat, alone.
- The pharmacodynamics, pharmacokinetics and safety of verinurad in combination with allopurinol 300 mg once daily have not previously been investigated in subjects with gout in comparison with allopurinol 300 mg once daily, 600 mg once daily or 300 mg twice daily alone.

What does this study add?

- Verinurad at doses of 2.5–20 mg in combination with allopurinol 300 mg once daily produced dose-dependent lowering of sUA levels. Verinurad at doses ≤5 mg in combination with allopurinol 300 mg once daily produced greater sUA lowering than allopurinol 600 mg once daily or 300 mg twice daily alone.
- Allopurinol 600 mg produced equivalent sUA lowering when administered once or twice daily.

How might this impact on clinical practice?

- If approved, verinurad in combination with an XOI may represent an effective treatment option in patients with gout who have an incomplete response to an XOI alone, providing a greater sUA lowering than dose escalation of XOI.
Current ULTs can be grouped by their mechanism of sUA reduction: the xanthine oxidase inhibitors (XOIs) allopurinol and febuxostat reduce urate production, while the uricosuric agents probenecid, benz bromor amine, sulfinpyrazone and lesinurad increase renal excretion of uric acid by inhibiting its reabsorption. Finally, the injectable uricases—for use in patients with severe tophaceous gout—enzymatically degrade uric acid to allantoin.

Allopurinol is the most widely prescribed first-line ULT for gout. Dosing recommendations for allopurinol are to start at ≤100 mg/day to reduce the risk of allopurinol hypersensitivity syndrome and to titrate in 100 mg/day increments every 2–4 weeks while monitoring sUA to achieve and maintain a target sUA of <6 mg/dL (or <5 mg/dL in patients with severe gout symptoms). Allopurinol is approved at a daily dose up to 800 mg (USA) or 900 mg (Europe), although in practice few patients receive more than 300 mg, in part due to physicians’ concerns over the safety of higher doses. The majority of patients fail to achieve their target sUA on allopurinol monotherapy. For these patients, guidelines recommend switching to febuxostat monotherapy or combining treatments with complementary mechanisms of action, such as an XOI with a uricosuric agent.

Lesinurad is a uricosuric agent approved in combination with allopurinol or febuxostat for the treatment of hyperuricaemia associated with gout in patients failing to achieve target sUA on an XOI alone. In the phase III clinical development programme, treatment with lesinurad at 200 mg and 400 mg doses in combination with febuxostat resulted in more patients achieving target sUA and experiencing reduction in overall tophus area compared with febuxostat alone. Neither the lesinurad 200 mg nor 400 mg dose combinations significantly reduced gout flares versus febuxostat alone at 12 months; however, the 400 mg combination did trend lower. The 400 mg lesinurad dose was associated with increased renal adverse effects (compared with lesinurad 200 mg plus febuxostat or febuxostat alone) and was neither submitted to, nor approved by, US and European regulatory agencies.

The clinical trial experience with ULTs demonstrates that more precipitous and increased lowering of sUA below target levels may lead to improved outcomes (eg, lower gout flare incidence, more rapid tophus area reduction).

Verinurad, a next-generation uric acid transporter (URAT1) inhibitor, demonstrates high potency in inhibiting URAT1. Verinurad at doses as low as 2.5 mg produces significant sUA lowering in humans, and this significant dose-dependent reduction in sUA may lead to improved outcomes and medical benefits for patients with gout. As observed for other uricosurics, verinurad monotherapy has been associated with elevated concentrations of urinary uric acid and instances of serum creatinine (sCr) elevation. XOIs, by contrast, are known to reduce urinary uric acid excretion by inhibiting urate production and the combination of an XOI with verinurad has been shown to maintain pretreatment levels of urinary uric acid excretion. Coadministration of an XOI with verinurad may therefore mitigate the renal effects of verinurad monotherapy, while lowering sUA to a greater extent than with either agent alone at the same dose.

Verinurad studies in healthy volunteers show that ~64% of a single oral 10 mg dose is absorbed, with a median time to maximum observed plasma concentration (Tmax) of 0.5 hours and a terminal half-life of 15 hours.

The current study evaluated the pharmacodynamics (PD), pharmacokinetics (PK) and safety of multiple doses of verinurad in combination with allopurinol compared with allopurinol monotherapy in adults with gout (NCT02498652). The doses of allopurinol monotherapy investigated included 300 mg once daily, 600 mg once daily and 300 mg twice a day. In addition to investigating dose combinations of verinurad with allopurinol, this study therefore provides a direct comparison of the PD of allopurinol 600 mg when administered once or twice daily.

**METHODS**

**Subjects**

This phase IIa, randomised, open label, multicentre study investigated subjects with a diagnosis of gout according to American Rheumatism Association Criteria. Subjects were required to be aged ≥18 and ≤75 years with a body weight ≥50 kg, body mass index (BMI) ≥18 to ≤45 kg/m², sUA ≥8 mg/dL and estimated sCr clearance ≥60 mL/min calculated by the Cockcroft-Gault formula using ideal body weight.

The study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki. Subjects provided informed consent to participate in the study. The study was performed from July to November 2013.

**Study design**

Two cohorts of subjects were randomised by incomplete block design to one of eight treatment sequences that included allopurinol (300 mg once daily) in combination with varying verinurad doses (Cohort 1: 2.5–15 mg, Cohort 2: 5–20 mg) or allopurinol 300 mg once daily, 600 mg once daily or 300 twice daily alone. Randomisation used a centralised Interactive Web Response System that generated a unique randomisation number for each subject. Treatment sequences were randomised to avoid a ‘sequence effect’ (figure 1). Each treatment period was 7 days, which combined a period for washing out the previous treatment and for stabilising the new treatment.

Subjects on prior ULT were started on colchicine 0.6 mg for gout flare prophylaxis at the beginning of ULT washout on approximately day −14. Subjects not on ULT started colchicine on approximately day −7. Verinurad and allopurinol 300 mg once daily or 600 mg once daily were administered approximately 30 min after a standardised breakfast (approximately 650 kcal and 35%...
fat). For allopurinol 300 mg BID, the second allopurinol dose was given in the evening after a meal, approximately 10 hours after the first dose.

**Blood and urine sampling**

Serum samples for PD analyses were collected at screening and at frequent preset intervals on baseline (day −1) and days 7, 14, 21, 28 and 35. Serial blood samples for PK analyses were collected on days 7, 14, 21, 28 and 35. Plasma was isolated from the blood by centrifugation. Urine samples (total catch) for PD and PK analyses were collected at 1-hour intervals rising to 2-hour or 10-hour intervals. Baseline sUA and sCr concentrations were assessed on day −2.

On PD/PK urine collection days, subjects were instructed to drink 240 mL of water immediately on waking (within 2 hours predose) to maintain their urine output. Study medication was administered with another 240 mL of water. After dosing, subjects were instructed to drink ~160 mL of water per hour for the next 12 hours with an additional 240 mL at 22 hours.

**Analytical methods**

Verinurad, allopurinol and oxypurinol concentrations in plasma and urine were measured by Ardea Biosciences (San Diego, California, USA). Plasma samples were extracted by protein precipitation and analytes quantified by high-performance liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) detection, while urine samples were prepared by dilution with water and quantified by high-performance LC-MS/MS. Assay performance information is included in the online Supplementary file 1.

**End points and determinations**

All subjects who received at least one dose of verinurad or allopurinol with evaluable PD or PK data were included in the PD and PK populations. All subjects who received at least one dose of verinurad or allopurinol made up the safety population.

The primary study objective was an assessment of the multiple-dose PD of verinurad in combination with allopurinol compared with allopurinol alone. The PD of allopurinol 600 mg once daily versus 300 mg twice daily was additionally compared. Planned PD parameters included maximum percent change in sUA from baseline ($E_{max}$), mean time-matched percent change in sUA from baseline (day −1), rate of urinary uric acid excretion, renal clearance of uric acid and fractional excretion of uric acid for each 24-hour collection period.

For PD analyses, a mixed-effects model was used on $E_{max}$, with sequence and treatment as fixed effects, subject as a random effect and baseline value as a covariate. The least-squares means for each treatment group and between-treatment differences, along with 95% CIs and $P$ values were estimated for each cohort. All statistical testing was conducted at an alpha level of 0.05. No adjustments were made for multiple comparisons. For summary statistics, data were pooled across cohorts according to allopurinol treatment. PD data were collected by Covance Central Laboratory Services (Indianapolis, Indiana, USA) and analyses were performed using SAS V.9.3 or later.
PK assessments investigated the dose proportionality of verinurad 2.5–20 mg in the presence of allopurinol 300 mg and the comparative PK of allopurinol 300 mg twice daily versus 600 mg once daily, using a power model in Phoenix WinNonlin software V.6.3 (Pharsight Corporation, Mountain View, California, USA). PK parameters for verinurad, allopurinol and oxypurinol (the main metabolite of allopurinol) included maximum observed plasma concentration (C_{max}), T_{max}, area under the plasma concentration–time curve from time zero to 24 hours postdose (AUC_{0–24}), and from time zero to the last measurable time point (AUC_{last}), plasma terminal half-life (t_{1/2}), amount excreted in urine (Ae_{0–24}), fraction excreted in urine as unchanged drug or metabolite (f_{e,0–24}) and renal clearance from time zero to 24 hours postdose (CL_{R,0–24}).

For PK analyses, a mixed-effects model was used on AUC_{0–24}, C_{max} and CL_{R,0–24} with treatment (allopurinol in the presence of verinurad vs allopurinol alone) as a fixed effect and subject as a random effect. Geometric mean (90% CI) PK parameters of allopurinol and oxypurinol are presented in the presence of varying verinurad doses versus allopurinol 300 mg once daily alone. Additionally, a fixed-effect analysis of variance model was used to compare the C_{max} and AUC_{0–24} of allopurinol and oxypurinol between the two parallel allopurinol dose groups (allopurinol 600 mg once daily vs 300 mg twice daily). In the twice daily regimen, AUC_{0–24} values for allopurinol or oxypurinol were extrapolated based on concentration profiles following the morning dose (estimated as 2×AUC_{0–12h}). PK analyses were conducted by Ardea Biosciences, using Phoenix WinNonlin V.6.3.

Subjects were monitored for safety throughout the study and at follow-up on day 49 (±2). Safety assessments included adverse events (AEs) coded according to the Medical Dictionary for Regulatory Activities (V.17.0), clinical laboratory evaluations, vital signs, electrocardiograms and physical examinations. AEs were defined as serious if they resulted in death, were life threatening, required hospitalisation or prolongation of existing hospitalisation or caused persistent or significant disability/incapacity. Any renal serious AEs were to be reviewed by a Renal Events Adjudication Committee appointed by the sponsor. Subjects were monitored for safety assessments and AEs within the study and at the end of the study. Safety results were summarised by descriptive statistics using SAS V.9.3 or later.

### RESULTS

#### Subjects

A total of 41 subjects were randomised to treatment in one of the two cohorts (n=20, Cohort 1; n=21, Cohort 2). Forty subjects completed the study as per protocol. One randomised subject in Cohort 2 was withdrawn because of non-compliance/protocol violation.

| Table 1 | Demographic characteristics and serum urate levels |
|---------|--------------------------------------------------|
| Cohort 1 | Cohort 2 | Overall |
| (n=20) | (n=21) | (n=41) |
| Age, years, mean (SD) | 50 (12.7) | 48 (10.9) | 49 (11.7) |
| Sex (n, %) | | | |
| Male (n, %) | 19 (95.0) | 21 (100) | 40 (97.6) |
| Female (n, %) | 1 (5.0) | 0 | 1 (2.4) |
| Body weight, kg, mean (SD) | 97.6 (22.7) | 97.4 (19.2) | 97.5 (20.7) |
| Body mass index, kg/m², mean (SD) | 32.0 (6.2) | 31.7 (5.8) | 31.9 (5.9) |
| Race (n, %) | | | |
| Asian | 3 (15.0) | 1 (4.8) | 4 (9.8) |
| Black or African American | 3 (15.0) | 3 (14.3) | 6 (14.6) |
| White | 14 (70.0) | 17 (81.0) | 31 (75.6) |
| Ethnicity (n, %) | | | |
| Hispanic or Latino | 8 (40.0) | 11 (52.4) | 19 (46.3) |
| Not Hispanic or Latino | 12 (60.0) | 10 (47.6) | 22 (53.7) |
| Serum urate, mg/dL, mean (SD) | 9.0 (1.05) | 9.2 (1.30) | 9.1 (1.17) |

The demographic and baseline characteristics of the subjects are summarised in table 1. Forty subjects were male and the majority (75.6%) were white. Mean age, weight and body mass index (BMI) were similar between the cohorts. The overall mean (SD) serum urate at baseline was 9.1 (1.17) mg/dL.

#### Pharmacodynamics

The time course of mean per cent change in serum urate from baseline (time matched) is shown in figure 2. The mean time to E_{max} ranged from 7 to 12 hours postdose for each treatment. Verinurad (2.5–20 mg) combined with allopurinol 300 mg once daily decreased E_{max} in a dose-dependent manner (figure 3). Least-squares mean E_{max} was 47%, 59%, 60%, 67%, 68% and 74%, respectively, for verinurad doses of 2.5, 5, 7.5, 10, 15 and 20 mg in combination with allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, allopurinol 600 mg once daily and allopurinol 300 mg twice daily alone. Verinurad at all doses combined with allopurinol 300 mg once daily produced significantly greater E_{max} than allopurinol 300 mg alone, while verinurad doses ≥5 mg combined with allopurinol 300 mg once daily produced greater E_{max} than allopurinol 600 mg once daily or 300 mg twice daily alone (P<0.05, all comparisons within each cohort). Allopurinol 600 mg once daily was equivalent to allopurinol 300 twice daily in E_{max} (figure 3).

Because of difficulty with the storage conditions of the samples, urinary PD samples, urinary uric acid PD parameters...
Crystal arthropathies could not be determined accurately and are therefore not reported.

Pharmacokinetics
Mean plasma concentration profiles of verinurad in combination with allopurinol are shown in figure 1 in the online Supplementary file 2. The median T_{max} of verinurad ranged from 3.00 to 3.97 hours and the mean t_{1/2} ranged from 9.4 to 20.0 hours postdose for varying doses of verinurad in combination with allopurinol 300 mg once daily (table 2). Increases in verinurad C_{max} and AUC were dose dependent (table 2; figure 1 in the online Supplementary file 2).

Figure 2 Mean (SE) per cent change from baseline in serum urate (mg/dL) following once-daily oral administration of varying verinurad doses in combination with allopurinol 300 mg once daily versus allopurinol 300 mg once daily, 300 mg twice daily or 600 mg once daily alone.
Verinurad did not affect the plasma PK of allopurinol, but dose dependently reduced oxypurinol \( C_{\text{max}} \) by 19.0%–32.4% and \( \text{AUC}_{\text{last}} \) by 20.8%–39.2% (table 3). Allopurinol administered as a single 600 mg dose produced comparable AUCs to divided 300 mg doses for allopurinol (least-squares geometric mean ratios (90% CIs): 204 (162 to 257) for \( C_{\text{max}} \) and 128 (101 to 162) for \( \text{AUC}_{0\text{-}24} \)) and oxypurinol (122 (103 to 146) and 115 (93.0 to 143), respectively).

Urinary drug concentration measurements were not affected by the storage conditions. Verinurad \( \text{Ae}_{0\text{-}24} \) increased with verinurad dose in combination with allopurinol 300 mg once daily, from 17.8 µg at 2.5 mg verinurad to 165 µg at 20 mg verinurad. Verinurad \( \text{fe}_{0\text{-}24} \) ranged from 0.63% to 0.87% (table 2) and \( \text{CL}_{\text{Rc-24}} \) from 8 to 11 mL/min.

Allopurinol \( \text{Ae}_{0\text{-}24} \) and \( \text{CL}_{\text{Rc-24}} \) were generally unchanged by verinurad at any dose, while oxypurinol \( \text{Ae} \) increased by 5%–29% and \( \text{CL}_{\text{Rc}} \) by 32%–101% with increasing verinurad doses relative to allopurinol 300 mg once daily alone (table 3).

**Safety**

Twelve subjects reported 23 treatment-emergent AEs (TEAEs). The most common individual TEAEs (in >5% of subjects) in the combined cohorts were upper

### Table 2

| Verinurad (mg) | \( C_{\text{max}} \) (ng/mL) | \( \text{AUC}_{0\text{-}24} \) (ng·hour/mL) | \( T_{\text{max}} \) (hour) | \( \text{t}_{\text{1/2}} \) (hour)* | \( \text{fe}_{0\text{-}24} \) (%) |
|---------------|-------------------------------|-----------------------------------------------|-----------------------------|---------------------------------|------------------|
| 2.5           | 4.28 (3.33–5.49)               | 33.9 (25.4–45.3)                              | 3.83 (0.967–9.83)           | 9.40 (6.97–12.7)                | 0.711 (0.462–1.09) |
| 5             | 8.20 (7.17–9.37)               | 68.4 (56.1–83.2)                              | 3.83 (1.97–8.02)           | 13.4 (10.0–17.8)               | 0.844 (0.600–1.19) |
| 7.5           | 11.2 (9.07–13.7)               | 92.0 (74.8–113)                               | 3.00 (1.00–9.97)           | 12.0 (8.33–17.4)               | 0.679 (0.500–0.920) |
| 10            | 15.3 (13.1–18.0)               | 145 (125–167)                                 | 3.43 (1.50–6.02)           | 20.0 (12.2–32.8)               | 0.868 (0.669–1.13) |
| 15            | 22.5 (18.6–27.2)               | 194 (158–238)                                 | 3.88 (1.00–6.02)           | 12.4 (8.12–19.0)               | 0.634 (0.463–0.869) |
| 20            | 27.6 (23.2–32.7)               | 261 (218–313)                                 | 3.97 (1.50–6.02)           | 15.8 (11.2–22.3)               | 0.824 (0.589–1.15) |

*Terminal \( t_{\text{1/2}} \) values were presented as median (range).

**T_{\text{max}}** values were calculated from a period of less than twofold of the calculated \( t_{\text{1/2}} \) value in more than half the subjects in the same dose group.

\( \text{AUC}_{0\text{-}24} \): area under the plasma concentration–time curve from time zero to 24 hours postdose; \( C_{\text{max}} \): maximum observed concentration; \( \text{fe}_{0\text{-}24} \): fraction excreted in urine as unchanged drug or metabolite; \( T_{\text{max}} \): time of maximum observed plasma concentration.
Table 3  Plasma and urine pharmacokinetics of allopurinol and oxypurinol following once-daily oral administration of varying verinurad doses in combination with allopurinol 300mg once daily (geometric means and geometric least-squares mean ratios, 95% CIs)

| Verinurad (mg) | Allopurinol | | | | Oxypurinol | | | | | |
|---------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | Cmax (µg/mL) | AUCo-Cmax (µg hour/mL) | Cmax (µg/mL/min) | Cmax (µg/mL) | AUCo-Cmax (µg hour/mL) | Cmax (µg/mL/min) | Cmax (µg/mL) | AUCo-Cmax (µg hour/mL) | Cmax (µg/mL/min) | Cmax (µg/mL) |
| 0 | 1.18 (1.03 to 1.36) | 3.70 (2.38 to 4.13) | 9.13 (82.1 to 101) | - | - | - | - | - | - | - |
| 2.5 | 1.16 (0.911 to 1.47) | 3.59 (2.87 to 4.49) | 8.20 (67.8 to 99.2) | 103 (90.7 to 117) | 100 (94.3 to 107) | 92.1 (86.2 to 98.3) | 10.2 (9.1 to 11.8) | 199 (171 to 233) | 18.4 (16.2 to 21.0) | 81.0 (75.9 to 86.5) |
| 5 | 1.16 (0.937 to 1.43) | 3.76 (3.20 to 4.41) | 7.66 (70.1 to 88.2) | 92.6 (78.1 to 110) | 98.0 (90.4 to 106) | 87.6 (91.6 to 92.5) | 9.39 (9.46 to 10.4) | 181 (161 to 202) | 21.7 (19.2 to 24.6) | 79.8 (70.5 to 84.7) |
| 10 | 1.11 (0.928 to 1.33) | 3.53 (2.99 to 4.16) | 8.64 (75.2 to 99.2) | 88.9 (78.4 to 101) | 92.0 (86.7 to 97.7) | 96.2 (91.2 to 101) | 8.76 (7.96 to 9.64) | 164 (147 to 182) | 25.9 (22.7 to 29.6) | 74.4 (70.5 to 78.6) |
| 15 | 1.12 (0.877 to 1.44) | 3.53 (2.84 to 4.39) | 7.35 (61.2 to 86.3) | 100 (87.7 to 114) | 98.9 (91.0 to 107) | 85.2 (78.2 to 92.3) | 8.54 (7.62 to 9.58) | 153 (133 to 176) | 25.7 (22.2 to 29.7) | 67.6 (61.1 to 74.9) |
| 20 | 1.26 (1.02 to 1.54) | 3.74 (3.21 to 4.34) | 8.22 (75.7 to 89.3) | 97.5 (89.8 to 102) | 90.7 (86.7 to 96.0) | 8.38 (7.58 to 9.28) | 151 (136 to 168) | 30.0 (26.8 to 33.5) | 71.3 (66.4 to 76.5) | 64.2 (59.6 to 69.1) |

AUCo-Cmax, area under the plasma concentration-time curve from zero to the last measurable time point; CL0–24, renal clearance from time zero to 24 hours; Cmax, maximum observed concentration; GMR, geometric least squares mean ratio.
benzbromarone (other URAT inhibitors) in combination with allopurinol also lower oxypurinol plasma exposure.\textsuperscript{11, 32} Despite the effect of verinurad on oxypurinol PK, it should be emphasised that the verinurad and allopurinol combination produced significantly greater sUA lowering than allopurinol alone.

All dose combinations of verinurad and allopurinol were generally well tolerated, with no serious AEs or renal-related events and no clinically meaningful changes in laboratory evaluations during treatment.

Limitations of the study include the short study duration, the inclusion of subjects with high mean sUA levels (>9 mg/dL) at baseline and the failure to obtain urinary uric acid data. Strengths of the study include the frequent blood samplings that increased the reliability of the PD and PK analyses, the inclusion of subjects with gout to ensure clinical relevance and the randomisation design that eliminated sequence effects.

In conclusion, oral verinurad at the doses studied (2.5–20 mg) in combination with allopurinol 300 mg once daily produced significantly greater sUA lowering than allopurinol 300 mg once daily alone in subjects with gout. Verinurad at doses ≥5 mg combined with allopurinol 300 mg once daily also produced significantly greater sUA lowering than allopurinol 600 mg alone, indicative of greater efficacy for this combination than for allopurinol dose escalation. All dose combinations of verinurad and allopurinol were generally safe and well tolerated, with no instances of sCr elevation. These data support continued investigation of oral verinurad in a dual-mechanism approach to lowering sUA.

Acknowledgements Editorial support for this manuscript was provided by Bill Wolvey of PAREXEL, which was funded by AstraZeneca.

Contributors All the authors contributed to the acquisition, analysis, interpretation of data for the work, drafting the work or revising it critically for important intellectual content and final approval of the version to be published. JNM, JH and MG were involved in the conception and design of the work

Funding Funding for this study was provided by Ardea Biosciences/ AstraZeneca.

Competing interests RF received a clinical study grant from Ardea Biosciences. FW is a full-time employee of Anaheim Clinical Trials. JNM, XY, LH, SV, JH, SL and ZS are/were full-time employees of Ardea Biosciences, a member of the AstraZeneca Group. MG is a full-time employee of AstraZeneca. MHR reports no conflict of interest.

Patient consent Obtained.

Ethics approval Schulman Associates IRB, Cincinnati, Ohio, USA.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement De-identified patient data from this study are made available for scientific research on a case by case basis through AstraZeneca’s Data Request Portal: https://astrazenecagroup-df.pharmaceutic.com/DT/Home/ Index/

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014;26:186–91.

2. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther 2015;32:31–41.

3. Bardin T, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol 2014;10:271–83.

4. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765–70.

5. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:25–42.

6. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007;56:1021–8.

7. Khanna D, Fitzgerald J, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46.

8. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529–36.

9. Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther 2015;17:120.

10. Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: the LASSO study. Semin Arthritis Rheum 2015;45:174–83.

11. Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomized, double-blind, placebo-controlled study in patients with gout who have inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017;76:811–20.

12. Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheum 2017;69:1903–13.

13. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study). Arthritis Rheumatol 2017;69:2033–12.

14. Pascual E, Andrés M, Vela P. Gout treatment: should we aim for rapid crystal dissolution? Ann Rheum Dis 2013;72:835–7.

15. Perez-Ruiz F, Calabozo M, Pijoan JL, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356–60.

16. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48(Suppl 2):i9–14.

17. Shiozawa A, Buysmans EK, Korser S. Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin 2017;33:117–24.

18. Terkeltaub R, Perez-Ruiz F, Kopicko J, et al. The safety and efficacy of lower serum urate levels: a pooled analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitors. Arthritis Rheumatol 2015;67:630–4.

19. Tan PK, Liu S, Gunic E, et al. Discovery and characterization of urinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 2017;7:665.

20. Gillen M, Miner JN, Valdez S. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese male subjects. Arthritis Rheum 2016;68(Suppl 10):1–4550. Abstract 193.1

21. VanderLugt J, Gillen M, Yang X, et al. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and febuxostat in healthy adult male subjects. Arthritis Rheum 2016;68(Suppl 10):1–4550. Abstract 191.

22. Shen Z, Gillen M, Miner JN, et al. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther 2017;11:2077–86.

23. Goldfarb DS, MacDonald PA, Hunt B, et al. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol 2011;38:1385–9.

24. Hall J, Gillen M, Liu S. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout. Arthritis Rheum 2016;68(Suppl 10). Abstract 194.
25. Lee C, Yang C, Shah V, et al. Metabolism and disposition of verinurad, a uric acid reabsorption inhibitor, in humans. Drug Metab Dispos. 2018. In press.

26. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895–900.

27. Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007;34:1401–14.

28. Fleischmann R, Kerr B, Yeh LT, et al. RDEA594-111 Study Group. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology 2014;53:2167–74.

29. Fleischmann R, Winkle P, Hall J. Pharmacodynamic effects and safety of verinurad in combination with febuxostat versus febuxostat alone in adults with gout: a phase 2a, open-label study. Arthritis Rheumatol 2016;68(suppl 10), Abstract 197.

30. Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005;33:1791–5.

31. Müller FO, Schall R, Groenewoud G, et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993;44:69–72.

32. Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 2016;75:1074–80.